AI-based CEST-MRF increases glutamate detection in MPTP mouse model, highlighting diagnostic potential.
Motivation: Previous glutamate CEST-weighted studies were unable to separate the confounding effects stemming from different proton pools. Goal(s): To develop a rapid and quantitative CEST MR Fingerprinting (MRF) pipeline for glutamate, amide, and semisolid MT imaging and validate it using a Parkinson's disease (PD) mouse model. Approach: An AI-based CEST-MRF framework was designed and used for imaging glutamate phantoms and MPTP PD mice (n=8). Results: In-vitro maps were in excellent agreement with ground truth (r=0.95, p<0.0001). The in-vivo maps exhibited significant increases in the glutamate and MT concentrations following MPTP treatment, in agreement with MRS. Impact: A multi-metabolite CEST-MRF quantitative approach was developed and validated using a mouse PD model. The extensive semisolid MT, amide and glutamate proton-exchange maps are expected to aid in the diagnosis and characterization of Parkinson's disease.
No takes yet. Share an insight, caveat, or question.
Shmuely et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: